251 related articles for article (PubMed ID: 27622314)
1. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension.
Kaufmann H; Norcliffe-Kaufmann L; Hewitt LA; Rowse GJ; White WB
J Am Soc Hypertens; 2016 Oct; 10(10):819-826. PubMed ID: 27622314
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson S; Vernino S; Ziemann A; Rowse GJ; Kalu U; White WB
J Am Soc Hypertens; 2016 Oct; 10(10):755-762. PubMed ID: 27614923
[TBL] [Abstract][Full Text] [Related]
3. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
Chen JJ; Han Y; Tang J; Portillo I; Hauser RA; Dashtipour K
Ann Pharmacother; 2018 Dec; 52(12):1182-1194. PubMed ID: 29972032
[TBL] [Abstract][Full Text] [Related]
4. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Palma JA; Norcliffe-Kaufmann L; Martinez J; Kaufmann H
Neurology; 2018 Oct; 91(16):e1539-e1544. PubMed ID: 30232253
[TBL] [Abstract][Full Text] [Related]
5. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
[TBL] [Abstract][Full Text] [Related]
6. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
7. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing and treating neurogenic orthostatic hypotension in primary care.
Kuritzky L; Espay AJ; Gelblum J; Payne R; Dietrich E
Postgrad Med; 2015; 127(7):702-15. PubMed ID: 26012731
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I; Arthur Hewitt L; Rowse GJ; Kaufmann H
BMC Neurol; 2017 May; 17(1):90. PubMed ID: 28494751
[TBL] [Abstract][Full Text] [Related]
10. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
11. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
Keating GM
Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
[TBL] [Abstract][Full Text] [Related]
12. Orthostatic hypotension is associated with nocturnal change in systolic blood pressure.
Voichanski S; Grossman C; Leibowitz A; Peleg E; Koren-Morag N; Sharabi Y; Shamiss A; Grossman E
Am J Hypertens; 2012 Feb; 25(2):159-64. PubMed ID: 22012209
[TBL] [Abstract][Full Text] [Related]
13. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
Isaacson SH; Skettini J
Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
[TBL] [Abstract][Full Text] [Related]
14. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Kaufmann H
Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
Patrick K; Martin T
JBI Database System Rev Implement Rep; 2017 Sep; 15(9):2287-2294. PubMed ID: 28902695
[TBL] [Abstract][Full Text] [Related]
16. Chemical pharmacotherapy for the treatment of orthostatic hypotension.
Cheshire WP
Expert Opin Pharmacother; 2019 Feb; 20(2):187-199. PubMed ID: 30376728
[TBL] [Abstract][Full Text] [Related]
17. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA; Hewitt LA; Isaacson S
J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
[TBL] [Abstract][Full Text] [Related]
18. [Ambulatory monitoring of blood pressure in orthostatic hypotension of Parkinson disease].
Senard JM; Rascol O; Chamontin B; Rascol A; Montastruc JL
Rev Neurol (Paris); 1993; 149(10):541-6. PubMed ID: 8023068
[TBL] [Abstract][Full Text] [Related]
19. The Association of Orthostatic Hypotension With Ambulatory Blood Pressure Phenotypes in SPRINT.
Ghazi L; Drawz PE; Pajewski NM; Juraschek SP
Am J Hypertens; 2021 May; 34(5):511-520. PubMed ID: 33186448
[TBL] [Abstract][Full Text] [Related]
20. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Goodman BP; Claassen D; Mehdirad A
Clin Auton Res; 2017 Jul; 27(Suppl 1):17-19. PubMed ID: 28631223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
